ClinicalTrials.gg
CompletedNCT00746798WinVax004Updated Apr 3, 2015Results posted

Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults

A Phase 2 interventional study of ChimeriVax-WN02 vaccine and ChimeriVax-WN02 vaccine in West Nile Fever, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 15 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-04-03.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
479
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine if ChimeriVax West Nile vaccine is safe and effective in preventing West Nile disease in adults over 50 years of age.

Read the detailed description

Currently, the only method of prevention of West Nile infection is control of the mosquito vectors associated or avoidance of mosquito bites, which has proven largely ineffective. Developing a safe, effective vaccine and making it widely available will enhance the prospects of prevention and control of this disease. In addition, natural infections with the YF virus and WN virus are more severe in the elderly. Therefore, a study among healthy older subjects or those with well controlled chronic diseases will provide data to determine a ChimeriVax-WN02 vaccine dose that is immunogenic and well tolerated.

02

Conditions studied

  • West Nile Fever

Keywords

  • West Nile Fever
  • ChimeriVax
  • West Nile Virus Vaccine
03

In context

Lead sponsor

Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.

Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.

First submitted after Sanofi Pasteur became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Medically stable, ambulatory male or female ≥ 50 years of age.
  • Attend all scheduled visits and to comply with all study procedures.
  • Negative serum pregnancy test at Screening, and a negative urine pregnancy test on Day 0.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected congenital or acquired immunodeficiency, therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term (at least 2 weeks within the previous 3 months) systemic therapy (at a dose of at least 10 mg of prednisone or equivalent), or depot preparation within the previous 3 months. Topical steroids are allowed.
  • Administration of immunoglobulins and/or any blood products within 3 months before enrollment or planned administration during treatment period of study.
  • Presence of acute or chronic illness associated with an oral temperature of >38.0 °C or requiring hospitalization at time of enrollment.
  • Any of the following serological findings at Screening:

positive surface antigen (HBsAg), positive (anti-HCV), or positive (HIV).

  • Personal or family history of thymic pathology (e.g., thymoma), thymectomy, or myasthenia.
  • History of significant allergic reaction to the vaccine components
  • Asplenia, functional asplenia, or any condition resulting in the absence or removal of the spleen.
  • Active or potentially progressive neurologic disease or injury including but not limited to: Parkinson's, Guillain Barré, epilepsy, seizures (except febrile seizures under the age of 2), cerebrovascular accident, head trauma requiring hospitalization within the preceding 3 years, or any other neurologic condition thought to impact the integrity of the blood brain barrier.
  • abnormal findings at Screening
  • Impaired hepatic function, and/or clinically significant or unexplained elevations of (ALT, SGPT), or aspartate aminotransferase (AST, SGOT) > 3X the .
  • Impaired renal function, as shown by but not limited to, serum creatinine >2.0 mg/dL.
  • Impaired hematopoietic function and/or clinically significant hematological laboratory abnormalities.
  • A history of alcohol or drug abuse within 12 months prior to study entry.
  • Pregnant or lactating women and women of who are not using an acceptable method of at least 28 days prior to enrollment. Post menopausal women will be considered not of childbearing potential 1 year after last menstrual period.
  • Behavioral, cognitive, or psychiatric disease that, in the opinion of the Investigator affects the ability of the subject to understand the scope of the study and/or unlikely to be able to be compliant with the study procedures and visits.
  • Any other condition, which in the Investigator's judgment, might result in an increased risk to the subject, or would affect the subject's participation in the study.
  • Participation in another clinical trial investigating a vaccine, drug or medical procedure in the 30 days preceding .
  • Any vaccine administered within 30 days prior to study vaccination. Note: Influenza vaccine can be administered 1 week preceding study vaccination.
  • Planned participation in another clinical trial during the present trial period.
  • Planned receipt of any vaccine in the 4 weeks following the trial vaccination.
  • Research site personnel or their family members cannot be enrolled as subjects in this trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
479 participants (actual)

Study arms

  • Experimental
    ChimeriVax WN02 vaccine, low dose

    Participants randomized to receive ChimeriVax WN02 vaccine, low dose

    Biological: ChimeriVax-WN02 vaccine

  • Experimental
    ChimeriVax-WN02 vaccine, medium dose

    Participants randomized to receive ChimeriVax-WN02 vaccine, medium dose

    Biological: ChimeriVax-WN02 vaccine

  • Experimental
    ChimeriVax-WN02 vaccine, high dose

    Participants randomized to receive ChimeriVax-WN02 vaccine, high dose

    Biological: ChimeriVax-WN02 vaccine

  • Placebo comparator
    Placebo

    Participants randomized to receive Placebo (Saline)

    Biological: Placebo

Interventions

  • BiologicalChimeriVax-WN02 vaccine

    low dose, approximately 4 x 3log10, given one time subcutaneously

  • BiologicalChimeriVax-WN02 vaccine

    medium dose, approximately 4 x 4log10, given one time

  • BiologicalChimeriVax-WN02 vaccine

    high dose, approximately 4 x 5log10, given one time subcutaneously

  • BiologicalPlacebo

    0.9%Normal Saline for Injection, given one time subcutaneously

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titers (GMTs) of Antibodies to Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine

    Antibodies to the vaccine antigens were measured by the Plaque Reduction Neutralization Test.

    Time frame: Day 0 and Day 28 post-vaccination

  2. Number of Participants With Seroconversion Following Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine.

    Antibodies to vaccine were measured by the Plaque Reduction Neutralization Test. Seroconversion was defined as a four-fold or greater rise in titer between pre- and post-injection samples; or a post-vaccination (Day 28) titers of ≥ 1:20 in participants with baseline titer ≤ 1:10.

    Time frame: Day 0 and Day 28 post-vaccination

  3. Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine.

    Time frame: Day 0 up to Day 14 post-vaccination

Secondary outcomes

  1. Number of Participants Developing Viremia After Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine.

    Viremia is defined as number of subjects in the analysis population dose group with detected (≥ 20 Plaque forming units \[pfu\]/mL) viremia at the reported visit.

    Time frame: Day 2 up to Day 14 post-vaccination

07

Results

Posted Nov 2, 2011

Participant flow

Participants were enrolled from 03 October 2008 to 08 December 2008 in 15 clinical centers in the US.

Participant flow — Overall Study
MilestoneChimeriVax WN02 Vaccine Low DoseChimeriVax WN02 Vaccine Medium DoseChimeriVax WN02 Vaccine High DosePlacebo
Started122124113120
Completed121122110120
Not completed1230
Withdrew: Protocol violation0100
Withdrew: Withdrawal by subject0110
Withdrew: Death0020
Withdrew: Participant unable to return for visit1000

Outcome measures

PrimaryGeometric Mean Titers (GMTs) of Antibodies to Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine

Antibodies to the vaccine antigens were measured by the Plaque Reduction Neutralization Test.

Time frame:
Day 0 and Day 28 post-vaccination
Reported as:
Geometric mean · Titers
Geometric Mean Titers (GMTs) of Antibodies to Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine
TitersChimeriVax WN02 Vaccine Low DoseChimeriVax WN02 Vaccine Medium DoseChimeriVax WN02 Vaccine High DosePlacebo
Day 05.00 (5.00 to 5.00)5.76 (4.92 to 6.74)5.06 (4.94 to 5.20)5.22 (4.80 to 5.68)
Day 28688 (453 to 1047)600 (405 to 890)674 (464 to 978)5.93 (4.96 to 7.08)
SecondaryNumber of Participants Developing Viremia After Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine.

Viremia is defined as number of subjects in the analysis population dose group with detected (≥ 20 Plaque forming units \[pfu\]/mL) viremia at the reported visit.

Time frame:
Day 2 up to Day 14 post-vaccination
Reported as:
Number · Participants
Number of Participants Developing Viremia After Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine.
ParticipantsChimeriVax WN02 Vaccine Low DoseChimeriVax WN02 Vaccine Medium DoseChimeriVax WN02 Vaccine High DosePlacebo
Day 21010
Day 43328150
Day 62133290
Day 81919210
Day 10151881
Day 127570
Day 142020
PrimaryNumber of Participants With Seroconversion Following Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine.

Antibodies to vaccine were measured by the Plaque Reduction Neutralization Test. Seroconversion was defined as a four-fold or greater rise in titer between pre- and post-injection samples; or a post-vaccination (Day 28) titers of ≥ 1:20 in participants with baseline titer ≤ 1:10.

Time frame:
Day 0 and Day 28 post-vaccination
Reported as:
Number · Participants
Number of Participants With Seroconversion Following Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine.
ParticipantsChimeriVax WN02 Vaccine Low DoseChimeriVax WN02 Vaccine Medium DoseChimeriVax WN02 Vaccine High DosePlacebo
Number of Participants With Seroconversion Following Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine.1051101033
PrimaryNumber of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine.
Time frame:
Day 0 up to Day 14 post-vaccination
Reported as:
Number · Participants
Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine.
ParticipantsChimeriVax WN02 Vaccine Low DoseChimeriVax WN02 Vaccine Medium DoseChimeriVax WN02 Vaccine High DosePlacebo
Any Pain [N = 122, 123, 112, 120]14291012
Grade 3 Pain (Prevents daily activities)0100
Any Erythema [N = 122, 123, 112, 120]2400
Grade 3 Erythema (> 10 cm)0000
Any Swelling [N = 121, 123, 112, 120]1000
Grade 3 Swelling (> 10 cm)0000
Any Fever [N = 122, 123, 111, 120]0030
Grade 3 Fever (≥ 39.0 ºC or ≥ 102.1 ºF)0010
Any Headache [N = 122, 123, 112, 120]31343331
Grade 3 Headache (prevents daily activities)2331
Any Malaise [N = 122, 123, 112, 120]26262725
Grade 3 Malaise (Prevents daily activities)2432
Any Myalgia [N = 122, 123, 112, 120]28252220
Grade 3 Myalgia (Prevents daily activities)2210

Adverse events

Collected over Adverse events data were collected from the day of vaccination (Day 0) to up to 6 months post-vaccination.. Non-serious events are listed at a 5.00% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ChimeriVax WN02 Vaccine Low Dose—4/122 (3.3%)51/122 (41.8%)
ChimeriVax WN02 Vaccine Medium Dose—1/124 (0.8%)56/124 (45.2%)
ChimeriVax WN02 Vaccine High Dose—3/112 (2.7%)42/112 (37.5%)
Placebo—5/120 (4.2%)54/120 (45%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventChimeriVax WN02 Vaccine Low DoseChimeriVax WN02 Vaccine Medium DoseChimeriVax WN02 Vaccine High DosePlacebo
InfluenzaInfections and infestations0/1220/1240/1122/120
Atrial fibrillationCardiac disorders1/1220/1241/1120/120
Accidential poisoningInjury, poisoning and procedural complications0/1220/1241/1120/120
ArthralgiaMusculoskeletal and connective tissue disorders0/1220/1241/1120/120
Prostate cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1220/1241/1120/120
Angina pectorisCardiac disorders0/1220/1240/1121/120
Myocardial infarctionCardiac disorders0/1220/1240/1121/120
Vitello intestinal duct remnantCongenital, familial and genetic disorders0/1220/1240/1121/120
Benign neoplasm of thyroid glandNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1220/1240/1121/120
PneumoniaInfections and infestations1/1220/1240/112—
Most frequent other events
Most frequent other events
EventChimeriVax WN02 Vaccine Low DoseChimeriVax WN02 Vaccine Medium DoseChimeriVax WN02 Vaccine High DosePlacebo
HeadacheNervous system disorders31/12234/12433/11231/120
MalaiseGeneral disorders26/12226/12427/11225/120
Injection site painGeneral disorders14/12229/12410/11212/120
MyalgiaMusculoskeletal and connective tissue disorders28/12225/12422/11220/120
NasopharyngitisInfections and infestations4/1226/1246/1128/120
Upper respiratory tract infectionInfections and infestations4/1221/1242/1128/120
CoughRespiratory, thoracic and mediastinal disorders7/1223/1243/1127/120

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ChimeriVax WN02 Vaccine Low DoseChimeriVax WN02 Vaccine Medium DoseChimeriVax WN02 Vaccine High DosePlaceboTotal
<=18 years00000
Between 18 and 65 years72756276285
>=65 years50495144194
Age, Continuous
Age, Continuous(Years)ChimeriVax WN02 Vaccine Low DoseChimeriVax WN02 Vaccine Medium DoseChimeriVax WN02 Vaccine High DosePlaceboTotal
Mean63.1 ± 9.3962.9 ± 8.1063.4 ± 9.0162.2 ± 8.2862.9 ± 8.69
Sex: Female, Male
Sex: Female, Male(Participants)ChimeriVax WN02 Vaccine Low DoseChimeriVax WN02 Vaccine Medium DoseChimeriVax WN02 Vaccine High DosePlaceboTotal
Female76656364268
Male46595056211
Region of Enrollment
Region of Enrollment(Participants)ChimeriVax WN02 Vaccine Low DoseChimeriVax WN02 Vaccine Medium DoseChimeriVax WN02 Vaccine High DosePlaceboTotal
United States122124113120479
08

Study locations

15 sites
  • Advanced Clinical Research Inst.
    Anaheim, California 92801, United States
  • Lynn Health Science Institute
    Colorado Springs, Colorado 80909, United States
  • Miami Research
    South Miami, Florida 33143, United States
  • Advanced Clinical Research- Idaho
    Boise, Idaho 83642, United States
  • Idaho Falls Infectious diseases
    Idaho Falls, Idaho 83404, United States
  • Johnson County Clinical Trials
    Lenexa, Kansas 66219, United States
  • Vince & Associates
    Overland Park, Kansas 66211, United States
  • Bio-Kinetic
    Springfield, Missouri 65802, United States
  • Big Sky Clinical Research
    Butte, Montana 59701, United States
  • Infectious Disease Specialists, PC
    Missoula, Montana 59802, United States
  • Odyssey Research
    Fargo, North Dakota 88104, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Research Across America
    Dallas, Texas 75234, United States
  • Benchmark
    Fort Worth, Texas 76135, United States
  • Radiant Research
    Salt Lake City, Utah 84107, United States
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Jun 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2011, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2008
First posted
Sep 4, 2008
Start
Oct 2008
Primary completionActual
Jun 2009
CompletionActual
Dec 2009
Results first posted
Nov 2, 2011
Last update
Apr 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00746798
Responsible party
Sponsor
First posted
Sep 4, 2008
Start date
Oct 2008
Primary completion
Jun 2009
Completion
Dec 2009
Results posted
Nov 2, 2011
Last update
Apr 3, 2015

Study contacts

Medical Director
study director · Sanofi Pasteur Inc

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion